云南白药集团股份有限公司 2、药品事业群 2024 年经营情况如何？ 答：2024 年药品事业群主营业务收入 69.24 亿元，同比增长 11.8%， 单品销售过亿产品达 10 个。核心系列产品中，云南白药气雾剂销售 收入突破 21 亿元，同比增长超 26%；云南白药膏、云南白药胶囊、 云南白药创可贴、云南白药（散剂）均在上年销售收入基础上，实现 显著增长。其他品牌中药类产品增长亮眼，蒲地蓝消炎片销售收入近 2 亿元，同比大幅增长超 22%，血塞通胶囊、小儿宝泰康颗粒、参苓 健脾胃颗粒产品收入均破亿。植物补益类产品，气血康口服液销售收 入继续保持增长态势，同口径下同比增长约 14%。 投资者调研会议记录 时间：2025 年 7 月 9 日 地点：集团总部办公大楼 召开方式：现场调研 投资者：平安基金-王华、丁琳，信达证券-章钟涛、王留阳 参加人员：投资者关系管理-张昱、杨可欣 会议内容 1、请问公司 2025 年一季度业绩情况如何？ 答：2025 年第一季度，公司实现营业收入 108.41 亿元，同比增 长 0.62%；归母净利润 19.35 亿元，同比增长 13.67%；扣非归母净利 润 18.87 亿元， ...

云南白药集团股份有限公司 投资者调研会议记录 时间：2025 年 7 月 8 日 地点：集团总部办公大楼 召开方式：现场调研 答：（1）研发能力强、领军人才储备丰富：云南白药与北京大 学联合成立北大—白药国际医学研究中心，在公司首席科学家张宁教 授带领下，依托北大在药物开发领域的创新引领能力和人才储备，利 用北大的大数据资源与生信分析等前沿技术，高效进行药物新靶点的 发掘。同时，校企联动，建立高效的可开发性评价、体外活性评价、 动物模型与体内评价、临床研究评价等体系，打造基于大数据的源头 创新研发平台。（2）产业链整合能力强：云南白药通过子公司云核 医药整合天津、北京、上海、昆明等研发资源，并与国内顶尖科研机 构深化合作，加强构筑源头创新能力，同时积极与核药产业链相关部 门、科研院所、核药企业、医疗机构等建立和深化战略合作，加速在 核药产业链上、中、下游的布局。（3）前瞻性战略布局：2022 年云 南白药围绕国家医用同位素战略发展需求和北京大学核医学研究优 势，成立了中央研究院创新药物中心，在肿瘤、免疫等领域布局，打 造以精准诊疗、独具优势的核药为中心的创新药研发管线，较早地认 识到核药在解决国内临床患者未被 ...

Core Viewpoint - The sudden resignation of key executives at Aihua Pharmaceutical raises concerns about the company's performance, as it faces a significant decline in revenue and profit in the first quarter of 2025, despite its flagship product achieving over 1 billion in sales in 2023 [1][2][3]. Group 1: Executive Changes - The resignation of Vice President Chen Liang marks the second departure of a core executive within two months, following the retirement of senior executive Ma Xin [1][2]. - Aihua Pharmaceutical has seen four vice presidents leave in the past year, indicating instability in the management team [1]. - The appointment of new Vice President Xiao Lin, who has extensive experience in the pharmaceutical industry, suggests a strategic shift towards professional academic promotion [2][4]. Group 2: Financial Performance - In Q1 2025, Aihua Pharmaceutical reported a revenue of 663 million, a year-on-year decline of 56%, with net profit dropping over 70% to 59 million [2][3]. - The company's traditional products, such as the pediatric cough syrup, are facing growth bottlenecks, and a drastic reduction of 79% in sales expenses indicates a decline in channel momentum [3]. - Despite the challenges, the company maintains a gross margin of 54%, which may reflect a focus on cash flow management during the transition period [3]. Group 3: Strategic Direction - The management changes coincide with a potential strategic shift from advertising-driven growth to a more professional and academic approach in marketing [2][5]. - The company aims to balance innovation and product development while addressing the challenges posed by recent executive departures and declining financial performance [5][7]. - Aihua Pharmaceutical is attempting to find equilibrium between legacy practices and necessary transformations to sustain its market position [7].

本报（chinatimes.net.cn）记者于娜 北京报道 近日，济川药业公布的一个新动向引发投资者关注：其全资子公司收到国家药品监督管理局签发的1.1 类中药创新药小儿便通颗粒申报上市许可的《受理通知书》。 从百亿王牌蒲地蓝消炎口服液因说明书修订、调出地方医保等因素销量持续萎缩，到消化类主力产品雷 贝拉唑钠肠溶胶囊受集采冲击价格大幅下探，再到儿科大单品小儿豉翘清热颗粒增长动能减弱，济川药 业核心产品矩阵接连承压。2024 年营收、净利润同比双降，2025 年一季度业绩下滑幅度进一步扩大， 连续的业绩颓势让这家老牌药企面临前所未有的增长压力，曾经的行业光环逐渐褪色。 这款针对小儿便秘食积证的新药，在济川药业陷入业绩困境之际，被投资者寄予了突围的厚望，不过其 未来能否真正扛起"救市" 大旗，仍是未知数。 核心产品失势 作为国内"清热解毒、消化、儿科" 领域的中成药龙头，济川药业过往凭借蒲地蓝消炎口服液、小儿豉 翘清热颗粒、雷贝拉唑钠肠溶胶囊等拳头产品，取得了亮眼的成绩。从 2014 年至 2023 年，济川业绩增 速显著，净利润十年复合增速高达21.49% 。然而，市场风云变幻，如今的济川药业风光不再。 曾经 ...

Core Viewpoint - Yunnan Baiyao is advancing its innovation in the pharmaceutical sector, particularly with the recent approval of clinical trials for its JZ-14 capsule aimed at treating ulcerative colitis, marking a significant step in its research and development of innovative drugs [1][2] Group 1: Innovation and R&D - Yunnan Baiyao emphasizes innovation as the cornerstone of its high-quality development, integrating traditional Chinese medicine with modern drug development [2][6] - The company has a robust pipeline with 11 major traditional Chinese medicine projects under secondary development and 25 ongoing projects [4] - Recent clinical studies have shown promising results for products like Qixuekang Oral Liquid in improving vascular health and for Shulian Capsules in treating chronic prostatitis [4][5] Group 2: Product Development and Market Strategy - The company reported a revenue of 6.924 billion yuan from its pharmaceutical business in 2024, reflecting an 11.8% year-on-year growth, driven by its core products [3] - Yunnan Baiyao is not merely improving existing products but redefining their clinical and market value through technological innovation [5][6] - The company is actively pursuing secondary development of its existing products to enhance their clinical applications and market competitiveness [5][6] Group 3: Long-term Vision and Strategic Planning - Yunnan Baiyao is strategically positioning itself in the innovative drug market, with ongoing projects in nuclear medicine and antibody drugs [9][10] - The company has outlined a strategic plan for 2024-2028, focusing on revenue, profit, and asset growth to become a leading modern pharmaceutical group [10] - Yunnan Baiyao is enhancing its R&D capabilities through multiple research centers and collaborations, including the application of AI in drug development [11]

国家药监局：批准江苏康缘阳光药业有限公司的七味通痹口服液为首家中药二级保护品种，保护期限自 公告日起七年。 ...

目前，长治市林下经济可利用种植面积达29.75万亩、可利用养殖面积达22.4万亩，林下种植中药材累计 16.7万亩左右，林下养殖累计18.55万头(只)左右，全市以党参、连翘、柏树果、酸枣仁浓缩口服液、蜂 蜜加工为主的林下经济产品加工企业达26家。今年，长治市计划新发展林下种植中药材4.5万亩，林下 种植菌类0.2万亩，林下养殖家畜2.0万头、家禽4.05万只；林产品加工预计年产值3.39亿元，全市林下经 济正向产业化、规模化、一体化方向发展。 从林间种植到森林康养，从传统资源开发到全产业链延伸，长治市正以林下经济为笔，在太行太岳的群 山间绘就一幅生态美、产业兴、百姓富的乡村振兴新画卷。(记者高增玉) 屯留区连翘产业成规模、串成链的发展模式，是长治市发展林下经济的缩影。位居全省第二的森林覆盖 率是长治市厚实的家底，也是其发展林下经济的最大底气。长治市依托山林自然风景资源，积极推 行"林下+"发展模式，围绕林下种植、林下养殖、林下采集加工、森林旅游与森林康养"四大体系"，重 点打造林药、林草、林菌、林禽、林畜、林蜂"六大模式"，适度发展生态旅游、森林康养、自然教育等 绿色富民产业，把生态优势转化为发展优势，拓宽 ...

Core Viewpoint - China National Pharmaceutical Group Corporation (Sinopharm Group) is facing significant challenges with Taiji Group, which has experienced a dramatic decline in performance after a strong 2023, with a 20.72% drop in revenue and a 96.76% plunge in net profit in 2024 [1][3][9] Financial Performance - In 2024, Taiji Group's total revenue decreased by 20.72% to 12.386 billion yuan, while net profit fell by 96.76% to 26.6527 million yuan [1][3] - The company's net profit for 2024 was revised to reflect a 96.76% decline, significantly impacted by tax liabilities from subsidiaries [9][10] - Quarterly performance showed a severe drop in net profit, particularly in Q4, which contributed to the overall annual decline [4][5] Product Performance - Key products like Huoxiang Zhengqi Oral Liquid saw a sharp decline in sales, with 2024 sales volumes dropping to 96 million boxes from 231 million boxes in 2023 [8] - Other products also experienced significant sales declines, while only a few, such as sinusitis oral liquid, showed growth [8] Management and Governance - Recent personnel changes in the board of directors, with several resignations and new appointments from Sinopharm Group, indicate a shift in management strategy [5][6] - The effectiveness of the new management in reversing the company's fortunes remains uncertain as the deadline for resolving industry competition issues approaches [10] Strategic Challenges - The company is struggling with an aging product portfolio and has not introduced new blockbuster drugs in over a decade, relying heavily on existing products [8] - The upcoming deadline for Sinopharm Group's commitment to resolve competition issues poses additional pressure on Taiji Group to meet its revenue targets for the 14th Five-Year Plan [10]

湖北济川药业股份有限公司董事会 有关各方及联系方式 联系人：季文浩、吴卓 联系电话：021-68826021 董事会声明 一、本公司全体董事确信本报告书不存在任何虚假记载、误导性陈述或重大 遗漏，并对其内容的真实性、准确性、完整性承担法律责任。 关于 曹飞 要约收购事宜 致全体股东的报告书 董事会报告签署日期：二零二五年七月 三、本公司关联董事曹龙祥、曹飞、黄曲荣已回避对本报告书的审议表决， 本公司其他董事没有任何与本次要约收购相关的利益冲突。 释义 | 上市公司、公司、济川药业 | 指 湖北济川药业股份有限公司 | | --- | --- | | 收购人 指 | 曹飞 | | 济川控股 指 | 江苏济川控股集团有限公司 | | 西藏济川 指 | 西藏济川企业管理有限公司 | | 一致行动人 指 | 曹龙祥、济川控股、西藏济川 | | | 1,010 曹龙祥将其持有的济川控股 10.10%股权以 万元价格 | | 本次股权转让 指 | | | 转让给曹飞 | | | | 收购人曹飞以要约价格向除曹龙祥、济川控股及西藏济川 | | 本次收购、本次要约收购 | 指 以外的其他股东发出收购其所持有的上市公司全部无限 ...

Group 1 - Jilin Aodong (000623) participated in an investor relations event to enhance communication between investors and the company, showcasing its business scope which includes traditional Chinese medicine, chemical drugs, and health products [1] - The company has 628 production approval numbers, with 315 for traditional Chinese medicine, and aims to leverage its brand and product quality to enhance market value and sales of key products [1] - Jilin Aodong plans to cultivate multiple core products with over 100 million yuan in sales and accelerate the development of strategic products with a market potential of 10 billion yuan [1] Group 2 - The Yanbian Pharmaceutical project has completed several production facilities, which passed GMP compliance checks and are now contributing to revenue [2] - In 2024, the health business is expected to generate 212 million yuan in sales, accounting for 8.13% of total revenue, with over 200 health products produced and sold [2] - The company has 22 registered health food certificates and 85 filing certificates, with 43 products generating over 1 million yuan in sales [2] Group 3 - Jilin Aodong is enhancing brand awareness through diverse marketing strategies, including e-commerce and social media platforms like Douyin [3] - The company is focusing on the core value of traditional Chinese medicinal materials and aims to develop high-value projects through research and innovation [3] - The health product development system is driven by consumer health trends, emphasizing research and development of functional health products [3] Group 4 - The company is investing in core quality long-term equity securities and related pharmaceutical companies, collaborating with various funds to invest in biopharmaceuticals and internet healthcare [4] - Jilin Aodong aims to strengthen its research capabilities through indirect investments in distinctive and competitive biopharmaceutical projects [4] - The company is optimizing its financial asset allocation to create a positive cycle of financial capital supporting real industry growth [4]